Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Recurrence 1Lung Diseases 1Adenocarcinoma Of Esophagus 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × zimberelimab × Clear all
NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡